GB0222787D0 - Metastasis inducing compounds - Google Patents

Metastasis inducing compounds

Info

Publication number
GB0222787D0
GB0222787D0 GBGB0222787.4A GB0222787A GB0222787D0 GB 0222787 D0 GB0222787 D0 GB 0222787D0 GB 0222787 A GB0222787 A GB 0222787A GB 0222787 D0 GB0222787 D0 GB 0222787D0
Authority
GB
United Kingdom
Prior art keywords
inducing compounds
metastasis inducing
metastasis
compounds
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0222787.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Original Assignee
University of Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liverpool filed Critical University of Liverpool
Priority to GBGB0222787.4A priority Critical patent/GB0222787D0/en
Publication of GB0222787D0 publication Critical patent/GB0222787D0/en
Priority to AU2003273502A priority patent/AU2003273502A1/en
Priority to PCT/GB2003/004279 priority patent/WO2004031239A2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GBGB0222787.4A 2002-10-02 2002-10-02 Metastasis inducing compounds Ceased GB0222787D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0222787.4A GB0222787D0 (en) 2002-10-02 2002-10-02 Metastasis inducing compounds
AU2003273502A AU2003273502A1 (en) 2002-10-02 2003-10-02 Metastasis inducing compounds
PCT/GB2003/004279 WO2004031239A2 (en) 2002-10-02 2003-10-02 Metastasis inducing compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222787.4A GB0222787D0 (en) 2002-10-02 2002-10-02 Metastasis inducing compounds

Publications (1)

Publication Number Publication Date
GB0222787D0 true GB0222787D0 (en) 2002-11-06

Family

ID=9945131

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0222787.4A Ceased GB0222787D0 (en) 2002-10-02 2002-10-02 Metastasis inducing compounds

Country Status (3)

Country Link
AU (1) AU2003273502A1 (en)
GB (1) GB0222787D0 (en)
WO (1) WO2004031239A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061418A2 (en) * 2004-12-09 2006-06-15 Ingenium Pharmaceuticals Ag Methods and agents useful in treating conditions characterized by mucus hyperproduction/hypersecretion
GB0616929D0 (en) * 2006-08-26 2006-10-04 Univ Liverpool Antibodies, assays and hybridomas
WO2008026009A1 (en) * 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Protein
KR100982186B1 (en) * 2010-01-21 2010-09-14 전남대학교산학협력단 Novel tumor antigen protein agr2 and tumor antigenpeptide thereof
US9415088B2 (en) 2011-02-25 2016-08-16 The Board Of Trustees Of The Leland Stanford Junior University Use of AGR3 for treating cancer
CN102268089A (en) * 2011-07-05 2011-12-07 上海交通大学 AGR2 (Anterior Gradient-2) blocking antibody and application thereof
US10494676B2 (en) 2013-12-02 2019-12-03 Albert-Ludwigs-Universitaet Freiburg Process for the diagnosis of cancer by using exosomes
WO2017120274A1 (en) * 2016-01-08 2017-07-13 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from protocadherin fat1 as cancer biomarkers
CN109576229A (en) * 2018-12-13 2019-04-05 华中科技大学同济医学院附属协和医院 A kind of monoclonal antibody hybridoma cell strain and its application for secreting anti-AGR2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508652A (en) * 1996-08-23 2002-03-19 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド Novel human growth factor
WO1998041627A1 (en) * 1997-03-19 1998-09-24 Zymogenetics, Inc. Secreted polypeptides with homology to xenopus cement gland proteins
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
GB0023080D0 (en) * 2000-09-20 2000-11-01 Univ Liverpool Prognostic indicator
EP1425302A2 (en) * 2001-01-24 2004-06-09 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Also Published As

Publication number Publication date
WO2004031239A2 (en) 2004-04-15
WO2004031239A3 (en) 2004-05-27
AU2003273502A8 (en) 2004-04-23
AU2003273502A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
GB0202216D0 (en) Novel compounds
GB0205256D0 (en) Novel compounds
GB0202679D0 (en) Novel compounds
GB0206723D0 (en) Novel compounds
GB0222516D0 (en) Novel compounds
GB0222787D0 (en) Metastasis inducing compounds
GB0207246D0 (en) Novel compounds
GB0203299D0 (en) Novel compounds
GB0200025D0 (en) Novel compounds
GB0207450D0 (en) Novel compounds
GB0222788D0 (en) Metastasis inducing compounds
GB0212355D0 (en) Novel compounds
GB0204252D0 (en) Novel compounds
GB0205649D0 (en) Novel compounds
GB0203677D0 (en) Novel compounds
GB0203673D0 (en) Novel compounds
GB0201231D0 (en) Novel compounds
GB0201211D0 (en) Novel compounds
GB0200787D0 (en) Novel compounds
GB0200503D0 (en) Novel compounds
GB0200108D0 (en) Novel compounds
GB0204758D0 (en) Novel compounds
GB0204305D0 (en) Novel compounds
GB0202140D0 (en) Novel compounds
GB0204255D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)